This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026
by Kanishka Das
ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.
ATAIPositive Net Change CMPSPositive Net Change GHRSPositive Net Change
biotechs
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
by Ahan Chakraborty
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
TNGXPositive Net Change RVMDPositive Net Change ERASPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
by Zacks Equity Research
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.
VRTXPositive Net Change CRSPPositive Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
by Ahan Chakraborty
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
TNGXPositive Net Change RVMDPositive Net Change ERASPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
by Zacks Equity Research
Pacira gains a reimbursement boost as UnitedHealthcare separately covers Exparel in outpatient care, expanding access to non-opioid postsurgical pain treatment.
PCRXPositive Net Change AMRNNegative Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
by Zacks Equity Research
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
CPRXPositive Net Change PTCTPositive Net Change LQDANegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
by Zacks Equity Research
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
KYMRNegative Net Change SNYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
by Zacks Equity Research
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
VRDNPositive Net Change AMRNNegative Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
by Zacks Equity Research
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
COLLPositive Net Change AMRNNegative Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
by Zacks Equity Research
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
PCRXPositive Net Change ZBHPositive Net Change LQDANegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals